Abstract
This study aims to identify critical factors contributing to defects in Epodion rh-Erythropoietin Alfa syringes and propose strategies to minimize production flaws. Through Failure Modes and Effect Analysis (FMEA), the research identified cracking as the predominant defect, accounting for 43 out of 62 observed syringe flaws in a production batch of 162,332 units. The Risk Priority Number (RPN) calculation yielded a score of 162, indicating material-related issues as the primary concern. Consequently, the study recommends stringent quality testing of raw materials to enhance material strength and diminish product defects, thereby bolstering overall manufacturing quality. Highlights : The study aimed to investigate factors contributing to defective Epodion® rh-Erythropoietin Alfa syringes, with a focus on reducing cracks during manufacturing. A Failure Mode and Effect Analysis (FMEA) approach was used to identify the primary causes of failure, revealing cracking as the predominant issue affecting 43% of defective units. Enhanced quality control measures for raw materials prior to their utilization within the production process were recommended to minimize product defects. Keywords: Epodion, rh-Erythropoietin Alfa, syringes, FMEA, quality control.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
